Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852296 | 1.00 | ALDH1A1 (0.49) | ALDH1A1GAAMAPTKDM4EL3MBTL1 | |
| SCHEMBL7999163 | 0.88 | ALDH1A1 (0.46) | ALDH1A1GAAMAPTKDM4EL3MBTL1 | |
| SCHEMBL453717 | 0.82 | — | — | |
| SCHEMBL10483958 | 0.80 | GAA (0.48) | ALDH1A1GAAMAPTKDM4EL3MBTL1 | |
| SCHEMBL6788044 | 0.78 | ALDH1A1 (0.49) | ALDH1A1GAAMAPTKDM4EL3MBTL1 | |
| Hydrochloric Acid SCHEMBL8572236 | 0.78 | GAA (0.47) | ALDH1A1GAAMAPTKDM4EL3MBTL1 | |
| SCHEMBL6639903 | 0.78 | GAA (0.47) | ALDH1A1GAAMAPTKDM4EL3MBTL1 | |
| SCHEMBL165097 | 0.78 | TAAR1 (0.52) | ALDH1A1GAAMAPTKDM4EL3MBTL1 | |
| SCHEMBL19797822 | 0.78 | GAA (0.47) | ALDH1A1GAAMAPTKDM4EL3MBTL1 | |
| SCHEMBL10483978 | 0.78 | GAA (0.47) | ALDH1A1GAAMAPTKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | GENOSCO INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4142732-B1 | METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12384773-B2 | Thiazole compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025096979-A1 | THIAZOLE COMPOUNDS AS KIT INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-4469062-A1 | INHIBITORS OF CDK4/6 KINASE | Kinnate Biopharma Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-12006302-B2 | Tau PET imaging ligands | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-11 | — | — | US | disclosed |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-20230295119-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GOSSAMER BIO SERVICES INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-8093238-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-01-10 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| US-20100069361-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-03-18 | — | — | US | disclosed |
| WO-2009150240-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| EP-2076512-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-07-08 | — | — | EP | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008044022-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
| CN-1469876-A | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists | �Ʒ� | 2004-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | TPMT, CYP11B2, ABAT | ALDH1A1 198/4885GAA 158/4885MAPT 1247/4885 |
| US-20230295119-A1 | SUBSTITUTED PYRIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | IRAK3, TYK2, IRAK2 | ALDH1A1 3481/4885GAA 4098/4885MAPT 1860/4885 |
| US-12202817-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | ALDH1A1 1674/4885GAA 1395/4885MAPT 4441/4885 |
| US-20100069361-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | JAK1, MTOR, MOK | ALDH1A1 1714/4885GAA 1343/4885MAPT 1997/4885 |
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | CRBN, PSMB3, PSMB1 | ALDH1A1 2657/4885GAA 1126/4885MAPT 3675/4885 |
| US-12006302-B2 | Tau PET imaging ligands | MAPT, PSEN1, APP | ALDH1A1 4764/4885GAA 661/4885MAPT 1/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | ALDH1A1 2279/4885GAA 1760/4885MAPT 955/4885 |
| US-20250109122-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | ALDH1A1 1674/4885GAA 1395/4885MAPT 4441/4885 |
| US-20240140932-A1 | CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS | HAMP, SLC40A1, FANCI | ALDH1A1 1674/4885GAA 1395/4885MAPT 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.